Long-term safety and tolerability of valsartan in children aged 6 to 17 years with hypertension.

Valsartan was generally well tolerated, with an AE profile consistent with angiotensin receptor blockers in the overall population and in patients with underlying CKD. Long-term efficacy was maintained and a beneficial effect on proteinuria was observed.